Full-Time

Solutions Architect

United Therapeutics Corporation

United Therapeutics Corporation

Biotech company develops PAH therapies

No salary listed

Research Triangle, Durham, NC, USA

In Person

Category
Sales & Solution Engineering (1)
Required Skills
Kubernetes
Microsoft Azure
Python
SQL
Java
Docker
Microservices
AWS
REST APIs
DevOps
Linux/Unix
Google Cloud Platform
Requirements
  • Bachelor’s or Master’s Degree in computer information systems, business administration, computer science, or a related field.
Desired Qualifications
  • Experience architecting / designing solutions for Microsoft Azure.
  • Experience integrating technologies into in a Microsoft 365 (M365 / O365) Enterprise cloud environment and related core services including: Entra, Exchange Online, SharePoint Online.
  • Experience with relational database platforms (e.g., Microsoft SQL Server), including architecture, deployment models, and operational considerations (not including writing database code).
  • Familiarity with common web hosting platforms and web server technologies (e.g., IIS, Apache) and their role in enterprise solution architectures.
  • Experience designing and evaluating system integrations using common enterprise patterns (e.g., APIs, event-driven architectures, data exchange, middleware).
  • Experience with Robotic Process Automation (RPA) and low-code/no-code automation platforms (e.g., Microsoft Power Platform).
United Therapeutics Corporation

United Therapeutics Corporation

View

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1996

Simplify Jobs

Simplify's Take

What believers are saying

  • TETON-2 Tyvaso IPF data published in NEJM positions it as first inhaled anti-fibrotic.
  • Ralinepag phase 3 triples PAH patient base to 30,000 within two years of launch.
  • $3.8B cash enables $2B share repurchase and Tresmi 2026 soft-mist launch.

What critics are saying

  • Liquidia Yutrepia approval Q2 2026 cannibalizes Tyvaso nebulized sales down 22%.
  • Insmed TPIP phase 2 beats TETON-1 FVC by 32mL, steals IPF market share.
  • Merck gefapixant phase 3 win March 2026 delays Tyvaso IPF FDA approval.

What makes United Therapeutics Corporation unique

  • Tyvaso targets prostacyclin pathway with inhaled, DPI, and soft-mist formulations for PAH.
  • Lung Biotechnology PBC pioneers xenotransplantation via UKidney EXPAND trial started November 2025.
  • Public benefit corporation status drives organ manufacturing alongside PAH therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at United Therapeutics Corporation who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Holidays

Paid Vacation

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Professional Certification Support

Tuition Reimbursement

Stock Options

Company Equity

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Performance Bonus

Profit Sharing

Sabbatical Leave

Hybrid Work Options

Remote Work Options

Flexible Work Hours

ParentAL Leave

Company News

Yahoo Finance
Mar 19th, 2026
The Trade Desk and United Therapeutics emerge as mid-cap growth picks while Builders FirstSource stumbles

Here is a summary of the article: Investment analysis platform StockStory has identified two mid-cap stocks worth buying and one to avoid. The Trade Desk, a cloud-based advertising platform, trades at $23.53 per share with a market capitalisation of $11.21 billion. The company posted 22% annual revenue growth over the past two years and boasts a 20.3% operating margin. United Therapeutics, which develops treatments for chronic lung diseases, has a market capitalisation of $23.24 billion. The company achieved 16.9% annual revenue growth over two years whilst demonstrating strong free cash flow generation and improving returns on capital. StockStory advises avoiding Builders FirstSource, a construction materials manufacturer. The company experienced 5.7% annual sales declines over the past two years, with eroding returns on capital and declining earnings per share.

Yahoo Finance
Mar 14th, 2026
United Therapeutics publishes Tyvaso IPF data in NEJM, eyes first inhaled anti-fibrotic approval

United Therapeutics has published full Phase 3 TETON-2 trial data for nebulised Tyvaso in idiopathic pulmonary fibrosis in the New England Journal of Medicine. The study demonstrated preservation of lung function and reduced clinical worsening in IPF patients. If approved by the FDA, Tyvaso would become the first and only inhaled anti-fibrotic treatment for IPF, significantly expanding United Therapeutics' addressable market. The company's shares currently trade at $536.12, with one-year returns of 74.5%. The publication in a top-tier journal represents a significant milestone for the drug developer. Investors are now monitoring potential FDA review milestones and how IPF could influence revenue beyond the current $3.2 billion base, though regulatory or reimbursement challenges remain key risks.

Yahoo Finance
Feb 26th, 2026
United Therapeutics shares drop 7.2% on $790M revenue miss despite earnings beat

United Therapeutics shares fell 7.2% after the biotechnology company reported fourth-quarter revenue of $790.2 million, missing analysts' consensus estimates of over $805 million. Whilst revenue grew 7% year-over-year, Tyvaso sales, though up 12%, also fell short of projections. The company did beat earnings expectations with adjusted earnings of $7.70 per share versus the forecasted $7.10. However, the revenue miss overshadowed the earnings beat, prompting negative market reaction. The stock has shown relatively low volatility over the past year, with only eight moves greater than 5%. United Therapeutics is currently trading at $500.08 per share, near its 52-week high of $535.10. Shares are flat year-to-date.

Yahoo Finance
Feb 26th, 2026
United Therapeutics targets 2026 soft-mist inhaler launch, surpasses $3B in annual revenue

United Therapeutics reported fourth-quarter 2025 results, with full-year revenue surpassing $3 billion for the first time, representing 11% growth. Fourth-quarter revenue reached $790 million, whilst Tyvaso generated $464 million with dry-powder inhaler sales growing 24% year-over-year. The company plans to file its soft-mist treprostinil inhaler, Tresmi, for approval this year, targeting a 2026 commercial launch. Early studies suggest the device could reduce coughing by up to 90% compared to dry-powder alternatives. Near-term catalysts include a once-daily "super prostacyclin" readout next week and TETON-1 IPF trial results next month, with potential launch by June 2027. The company's Zeno xenotransplant programme has transplanted two patients, targeting a commercial product by 2030.

Yahoo Finance
Feb 25th, 2026
United Therapeutics misses Q4 revenue estimates despite 7.4% growth to $790M

United Therapeutics missed Wall Street's revenue expectations in Q4 2025, reporting $790.2 million against estimates of $810.4 million, though sales rose 7.4% year on year. The biotechnology company's GAAP profit of $7.70 per share beat analyst estimates by 14%. The company, which develops treatments for chronic lung diseases and pulmonary hypertension, has demonstrated solid long-term performance with 16.5% annualised revenue growth over five years. However, its operating margin declined to 45.1% from 48.6% in the prior-year quarter. Analysts expect revenue to remain flat over the next 12 months, representing a deceleration from recent growth rates. United Therapeutics has a market capitalisation of $20.38 billion.